Non-estrogen-dependent hyperproliferation of cells in animals or humans can be prevented or treated by means of a pharmaceutical or nutritional composition containing a combination of a) two or more inhibitors of the G1/S phase of the cell cycle； and b) two or more inhibitors of the G2/M phase of the cell cycle； and c) two or more inhibitors of protein tyrosine kinase activity. Especially, component a) comprises two or more compounds selected from flavanolignans, carotenoids and isoflavone； component b) comprises two or more compounds selected from flavanolignans, hydroxylated stilbenes, isoflavones and apigenin； and component c) comprises two or more compounds selected from flavanolignans and isoflavones.
